1. A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN‐BARR VIRUS (EBV)‐ASSOCIATED LYMPHOMAS. (12th June 2019) Authors: Porcu, P.; Haverkos, B.; Brem, E.; Vallurupalli, A.; Feldman, T.; Alpdogan, O.; Brammer, J.; Bryan, L.J.; Barta, S.; Schriefer, A.; Obrzut, S.; Shen, H.; Rochford, R.; Baiocchi, R.; Casper, C.; Gutheil, J.; Melink, T.; Kearns, C.; Burner, D.; McRae, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Survival Outcomes after First-Line Therapy in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Using a United States (US) Electronic Medical Record (EMR)-Based Cohort. (April 2017) Authors: Bell, J.; Galaznik, A.; Farrelly, E.; Blazer, M.; Seal, B.; Ogbonnaya, A.; Raju, A.; Eaddy, M.; Fram, R.; Faller, D. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗